Komori
Kissei Pharmaceutical (4547) · RiskMaterialised

Risks to Development and Marketing Rights Arising from Termination of Overseas Sublicense Agreement

First written in FY2024-Q3. 3 of 3 entries say "Materialised", first in FY2024-Q3. Latest entry: FY2025-H1.

3entries
1years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMaterialisedFY2024-Q3 – FY2025-H12024: 32024
Same theme, other companies
Reliance on External Partners, Including Licensors, Sales Partners and CROsA theme 100 companies write about · 103 as a headwind · 0 as a tailwind

Kissei Pharmaceutical moved to the "Worse" side of this theme in 2024, 1 year after the typical company in this theme (2023).

The whole theme swung hardest in 2020: 8 of 42 companies on the "Worse" side.

8 other companies' latest entry also says "Materialised".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 100 companies compared. The sentences above are computed from all 100.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1MaterialisedAnnual report

    「In September 2024, we notified バイオジェニュイン社 (China) of the termination of the license agreement granting it development and commercialization rights in China and other territories.」

    Notice of termination was given for the licensing agreement for linzagolix in China and other regions, newly giving concrete form to the risk of termination of the overseas sublicense agreement.
  2. FY2024MaterialisedAnnual report

    「The licensing agreement between the Company and Affamed Therapeutics (China), under which Affamed Therapeutics was granted development and sales rights for the Parkinson's disease treatment KDT-3594 in China and other regions, ended in May 2024.」

    The overseas licensing agreement for KDT-3594 in China and other regions ended, reducing the territory covered by the development and sales rights licence.
  3. FY2024-Q3MaterialisedAnnual report

    「The sublicense agreement we entered into with 印マジンバイオファーマシューティカルズ社 (China) granting development and commercialization rights for fostamatinib, a treatment for chronic immune thrombocytopenia, in China ended in December 2023.」

    The sublicense agreement for development and sales rights for R788 in China, including Hong Kong and Macau, ended in December 2023, and contractual uncertainty regarding the licensing of overseas development and sales rights materialised.
Moved together

"Expanding into Global Markets Through Out-Licensing of Proprietary Products" moved the same way as this thread, in the same document, in 3 of its 3 moves.

322★123
  1. ★This thread
  2. 1Expanding into Global Markets Through Out-Licensing of Proprietary Products3×
  3. 2Promoting overseas expansion and stabilizing the overseas earnings base2×
  4. 3Creating New Drugs Through Development Pipelines and External Partnerships2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kissei Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risks to Development and Marketing Rights Arising from Termination of Overseas Sublicense Agreement | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori